## PENNIE & EDMONDS LLP

1667 K Street, N.W., Washington, D.C. 20006 (202) 496-4400 Fax: (202) 496-4444

INTERNET ADDRESS: SIRAS@PENNIE.COM

P.01

WRITER'S DIRECT DIAL: (202) 496-4454

# TELEFACSIMILE MESSAGE

October 22, 2001

7853-242-999

Sender: Serge Sira, Ph.D.	Facsimile Number Your Reference
Pages (including this page): 6  Recipient Address  Office Of Petitions	703 308-6916
Recipient  U.S. PTO - Office Of Petitions  Examiner Cliff Congo	Confirmation copy will not follow.

Re:

U.S. Patent Application No.: To Be Assigned

For: Compositions and Methods for the Treatment Filed: August 7, 2001

and Diagnosis of Cardiovascular Disease

FAX RECEIVED

OCT 2 2 2001

PETITIONS OFFICE

### MESSAGE:

Further to your request, please find attached herewith copies of the Utility application transmittal sheet, date-stamped postcard and accompanying Petition Under 37 C.F.R. 1.137(b) to Revive Unintentionally Abandoned Application.

If you have any problems regarding this transmission, please contact Monica L. Mitchell at (202) 496-4614

The information contained in this facsimile message is information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the information contained in this facsimile message is information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the information contained in this facsimile message is information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the information contained in this facsimile message is information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the information contained in this facsimile message is information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the information contained in this facsimile message is information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the information contained in this facsimile message is information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the use of the information contained in this facsimile or any other reader. The information contained in this facsimile message is information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the information protected by attorney-client and/or the attorney work product privilege. It is intended only for the use of the information contained in this facsimile or attorney work product privilege. It is intended only for the use of the information contained in this facsimile is not the named recipient or the canologue or agent responsible to deliver it to the named recipient. and use, distending the intended only for the use of the information contained in this facsimile is not the named recipient or the canologue or agent responsible to deliver it to the named recipient. the individual named above and the privileges are not waived by virtue of this having been sent by facsimile. If the person actually receiving this facsimile or any other reader of the facsimile is not the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient. If you have received this communication in error, please immediately notify us by telephone and return the original measure to use of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, dissemination, distribution, or copying of the facsimile is not the named recipient or the employer or agent responsible to deliver it to the named recipient, any use, distribution, distribution, or copying of the facsimile is not the named recipient of the contribution of the facsimile is not the named recipient of the facsimile is not the named recipient of the facsimile is not the named recipient of the n

FAX RECEIVED OCT 2 2 2001

## PETITIONS OFFICE

	First Class Mail ( )
Express Mail NoHand Corry	Filed Concurrently berewith
Data Mailed August / August	
Ser. NoTo Re Assigned	R THE TREATMENT AND DIAGNOSIS OF
Inventor/Mark FALB et al.	R THE TREATMENT AND DIAGRAM
COMPOSITIONS AND METHODS TO	
For CARDIOVASCULAR DISEASE	- ·· · · - From
	Fee Address Indication form
D Declaration/Affidavit	a vee Colculation
Declaration Attication  Amendment and Response  Application pages Claims 21 Drawings	Issue Fee Transmittal
Application pages / 2/ Descripts	Letter Confirm
Claims A Drawings	□ Cral Hearing Req./Confirm. □ Petition to Extend Time (3 months) □ Petition 4 = 37 C.F.R.
Appeal, Notice of	D Pet under 37 C.F.R.
	D Power of Attorney
Brief (in pripicate)  Brief (in pripicate)  Brief (in pripicate)	
	Sequence Listing W/Computer  Sequence Listing W/Computer  Paper Copy only
Design Application	
Disclaimer Disclosure Statement	Small Entity Statement
Disclosure States. D w/e refs.	la Cietus Lettei
Drawings, Formal	
SheetsFigures	Transmittal Lener © Fee by Deposit Account 16-1150
Others:	<i>y</i> , .
A malieration of manufacture	Serial No. 09/034,286
Other: Continuation Application Penns Store	
	SenderLAC/SVSMLM
File No. 7853-242-999	Derices
File No	DC1 - 251598.1
	DC1 - 2313501-

**FAX RECEIVED** 

PENNIE & EDMONDS LLP DOCKET NO. 7853-242-999

OCT 2 2 2001

PETITIONS OFFICE

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior application:	Examiner D, Nguyen
•	Art Unit_1633
Assistant Commission Box PATENT APPI Washington, D.C. 20	ICATION
Sir:	
This pending prior applic	is a request for filing a ≅ continuation □ divisional application under 37 CFR § 1.53(b), of ation no. 09/034,286 filed on March 4, 1998.
of Dean A. FALB	et al. (inventor(s) currently of record in prior application)
	NS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF CARDIOVASCULAR
DISEASE	(title of invention)
1.	☑ The filing fee is calculated below:

#### PATENT APPLICATION FEE VALUE

ТҮРЕ	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	57	-20	37	\$18.00 each	\$ 666.00
Independent	6	-3	3	\$80.00 each	\$ 240.00
Basic Fee  Multiple Dependency Fee  If Applicable (\$270.00)  Total					\$ 710.00
					0.00
					\$ 1,616.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern			- \$ 0.00		
			Total Filing	Fee	\$ 1,616.00

- 2. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
- 3. Amend the specification by inserting before the first line the following sentence:
  This is a continuation of application no. 09/034,286, filed March 4, 1998.
- 4a. D New formal drawings are enclosed.

#### PENNIE & EDMONDS LLP DOCKET NO. 7853-242-999

- Informal drawings are enclosed. 4b. Priority of applicati n no. fil d on in is claimed under 35 U.S.C. §119. 0 5a. The certified copy has been filed in prior application no., filed. 5b. The prior application is assigned of record to Millennium Pharmaceuticals, Inc. & 6. 8 Brigham and Women's Hospital. The Power of Attorney appears in the original papers in the prior application no. 7a. X 09/034,286, filed March 4, 1998. Since the Power of Attorney does not appear in the original papers, a copy of the 7Ь. Power in prior application no., filed is enclosed.
- This application contains nucleic acid and/or amino acid sequences required to be 8. disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no. 09/034,286, filed on August 6, 1998 be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. 09/034,286 is enclosed.
- The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed 9. Ø paper Sequence Listing from application no. 09/034,286 is the same as the content of the computer readable form submitted in application no. 09/034,286.
- Additional enclosures or instructions. 10. Copy of application including drawings and executed declaration

Respectfully submitted,

Date August 7, 2001

Serge Sira

PENNIE & EDMONDS 112 1667 K. Street, N.W.

Washington, D.C. 20006

(202) 496-4400

For: Laura A. Coruzzi, Reg. No. 30,742

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, New York 10036-2711

Phone: (212) 790-9090